Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Lyra Therapeutics, Inc.
| Metric | Lyra Therapeutics, Inc. LYRAHealthcare |
|---|---|
| Quality Score | 36 / 100 |
| Revenue (latest) | $398,000 |
| Net income (latest) | −$29M |
| Operating margin | −7794.5% |
| Net margin | −7266.1% |
| Return on equity | 269.8% |
| Return on assets | −80.1% |
| Return on capital (ROCE) | −116.7% |
| Debt / equity | — |
| Revenue growth (YoY) | −74.1% |
| Altman Z″ (distress) | -43.94 |
| Accruals / assets | −0.2% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.